SOURCES:
William Schaffner, MD, professor of preventive medicine and infectious disease specialist, Vanderbilt University Medical Center, Nashville; medical director, National Foundation for Infectious Diseases.
Ann Falsey, MD, professor of medicine and respiratory viruses researcher, University of Rochester School of Medicine, Rochester, NY.
Aaron Glatt, MD, chair, Department of Medicine; chief of infectious diseases and hospital epidemiologist, Mount Sinai South Nassau; professor of medicine, Icahn School of Medicine at Mount Sinai, Oceanside, NY.
Leonard Friedland, MD, vice president and director, scientific affairs and public health, vaccines, GSK.
Pfizer spokesperson.
FDA: “FDA approves first respiratory syncytial virus (RSV) vaccine,” “FDA Roundup June 2.”
World Health Organization: “Respiratory Syncytial Virus (RSV) disease.”
CDC: “RSV Surveillance & Research,” “RSV Transmission,” “RSV Symptoms and Care.”
GSK: “US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults.”
Pfizer: “U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults.”
The New England Journal of Medicine: “Efficacy and Safety of a bivalent RSV Prefusion F Vaccine in Older Adults,”“Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants,”“Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.”
AstraZeneca: “Nirsevimab unanimously recommended by FDA Advisory Committee for the prevention of RSV lower respiratory tract disease in infants.”